ByTrending Posts
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape…
Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting BioNTech and Pfizer…
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence…
Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long IPO drought by…
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and…
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines…
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
Will AbbVie’s Rinvoq Patent Deal Lock Out Generics…
Key Highlights: Patent Shield Extended Through SettlementsAbbVie has successfully resolved litigation with multiple generic challengers—including Sandoz, Aurobindo, Intas,…
Will Johnson & Johnson’s FDA Approval of INLEXZO™…
Key Highlights: A Breakthrough in Bladder Cancer TreatmentThe U.S. FDA has approved INLEXZO™ (gemcitabine intravesical system), marking the…
Could Johnson & Johnson’s MARIPOSA Trial with RYBREVANT®…
Key Highlights: Clinical Breakthrough in EGFR-Mutated NSCLCJohnson & Johnson’s Innovative Medicine segment has announced positive results from the…
Can Novo Nordisk’s New Semaglutide and Obesity Pipeline…
Key Highlights: Scientific Momentum at EASD 2025Novo Nordisk will present 35 abstracts across its diabetes and obesity portfolio…
Could Pfizer and BioNTech’s LP.8.1-Adapted COMIRNATY® Redefine COVID-19…
Key Insights: Robust Phase 3 Findings for High-Risk PopulationsThe topline results from the Phase 3 clinical trial included…
Trending Posts
Latest Stories
Does the U.S. Exit from WHO Redefine Global Health Governance? Washington Completes Historic Withdrawal
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS and Janux Strike $850 Million T-Cell Engager Deal
January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS and Janux Strike $850 Million T-Cell Engager Deal
22 January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration…
Can Global Partnerships Future-Proof Epidemic Preparedness? SK bioscience, Merck (MSD), and Hilleman Unite to Strengthen Ebola Vaccine Supply
23 January 2026 Executive Summary A global vaccine partnership has been established between SK bioscience,…
Gallery
